Pulmonx Corp. believes it is close to finally earning US FDA approval for its Zephyr endobronchial valve, nine years after the agency rejected it and almost 20 years since it was first developed.
The Zephyr is a small silicone-covered stent-valve installed in the lungs via a minimally invasive procedure to block airflow to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?